Status:
UNKNOWN
68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Chemokine receptor-4 (CXCR4) is overexpressed in multiple myeloma (MM) cells. 68Ga-pentixafor is a radio-labled tracer for CXCR4 . 68Ga-pentixafor PET/CT has shown good diagnostic performance in MM. B...
Detailed Description
Multiple myeloma (MM) is a malignant plasma cell disorder which is characterized by clonal proliferation of plasma cell in bone marrow microenvironment. Chemokine receptor-4 (CXCR4) is overexpressed i...
Eligibility Criteria
Inclusion
- Suspected or confirmed untreated multiple myeloma (MM), relapsed MM, MM in remission
- Signed written consent
Exclusion
- pregnancy
- breastfeeding
- known allergy against pentixather or pentixafor
- any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.
Key Trial Info
Start Date :
August 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05364177
Start Date
August 11 2021
End Date
August 1 2024
Last Update
May 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100005